Better Buy: Exelixis, Inc. vs. Novartis AG
Novartis (NYSE: NVS) stands out as one of the biggest pharma companies with a broad array of products, including several of the most powerful cancer drugs on the market. Exelixis (NASDAQ: EXEL) only has three products on the market right now, but it ranks as one of the most promising rising stars in the treatment of cancer.
If you bought shares of both stocks, you'd be much happier with Exelixis so far in 2017. The biotech's share price has soared more than 70% year to date, while Novartis stock is up less than 15%. But which of these stocks is the better pick now? Here's how Exelixis and Novartis compare.
Both Exelixis and Novartis have great drugs to fight cancer. Image source: Getty Images.
Source: Fool.com
Exelixis Inc. Aktie
23,05 €
-1,51 %
Absolute Beliebtheit: Exelixis Inc. hat nur Buy-Einschätzungen.
Ein positives, wenn auch bescheidenes, Potenzial für Exelixis Inc. mit einem Kursziel von 26 € im Vergleich zum aktuellen Kurs von 23.05 €.
